Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kinesin family member 18B pseudogene 1 (KIF18BP1) is an unprocessed pseudogene that resembles the functional gene KIF18B but is not expected to be translated into a protein because it contains disabling mutations such as premature stop codons or frameshifts[1][3]. There are no published reports indicating a protein product, functional enzyme activity, or receptor function. Pseudogenes can sometimes act as regulatory RNAs if transcribed, competitively binding microRNAs and thereby affecting the regulation of their protein-coding "cognate" genes; however, there is no evidence in the literature or gene reports that KIF18BP1 is transcribed or has such a function[1][3][5]. It is therefore not regarded as a therapeutic target, nor is there evidence for use as a biomarker, target for drugs, or known safety/therapeutic concerns. Its primary classification remains as a pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kinesin family member 18B pseudogene 1 (KIF18BP1).